Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trough level-guided infliximab dose reduction in Crohn's disease
NL-OMON22458Phase 4Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in Crohn's disease (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Proportion of patients with sustained clinical remission. Planned start Apr 2014; status: withdrawn.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON22458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22458.